New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are likely to boost consumer demand, but employer-sponsored health insurance may not foot the bill.

About 43% of employers covered the drugs for weight-loss in 2025, and estimates for 2026 are about the same

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are likely to boost consumer demand, but employer-sponsored health insurance may not foot the bill.